RA
PCRX icon

RiverPark Advisors’s Pacira BioSciences PCRX Stock Holding History

RiverPark Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-20,132
Closed -$866K – 52
2018
Q4 		$866K Sell
20,132
-4,986
-20% -$233K 0.38% 49
2018
Q3 		$1.24M Sell
25,118
-3,953
-14% -$171K 0.3% 49
2018
Q2 		$932K Buy
29,071
+13,225
+83% +$457K 0.19% 59
2018
Q1 		$494K Buy
+15,846
New +$564K 0.1% 67
2017
Q4 		– Sell
-32,624
Closed -$1.23M – 77
2017
Q3 		$1.23M Hold
32,624
– – 0.16% 66
2017
Q2 		$1.56M Hold
32,624
– – 0.18% 61
2017
Q1 		$1.49M Hold
32,624
– – 0.1% 60
2016
Q4 		$1.05M Hold
32,624
– – 0.56% 53
2016
Q3 		$1.12M Hold
32,624
– – 0.24% 52
2016
Q2 		$1.1M Hold
32,624
– – 0.54% 52
2016
Q1 		$1.73M Buy
+32,624
New +$1.91M 0.81% 44

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return